Entering text into the input field will update the search result below

Inovio: Hold For Future DNA Plasmid Therapy Progress

Jan. 10, 2023 7:23 AM ETInovio Pharmaceuticals, Inc. (INO)12 Comments
William Meyers profile picture
William Meyers


  • Inovio’s stock price is near multi-year lows.
  • It was unable to bring a COVID vaccine to market.
  • It has a viable path to FDA approval for precancers caused by HPV.

3D Futuristic DNA interface with HUD and infographic elements. Virtual technology background. Science. Biology. Human. Chart.

Muhammet Camdereli

Inovio (NASDAQ:INO) seems to be a perpetually clinical phase biotechnology company. The stock price is down. I do not see any catalyst likely to send it significantly higher any time soon. Every step forward seems to be followed by

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of INO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (12)

Ino-5401 could be the game changer with Libtayo. I read that 1 child’s treatment of glioblastoma cost about $3 million for a new personally customized medicine. Inovio has an opportunity to enter this market and profit. There are about 10,000 glioblastoma patients in the world. Thank you for taking an honest look at the company. My feelings exactly.
William Meyers you have no vision of the DNA revolution about to take place. By the way you should try to be more careful in your spelling and less bashing about a DNA revolution about to take place in 2023

BTW It's.. VGX-3100 not VGS
@Mike Ardelli "BTW It's.. VGX-3100 not VGS"

I think he knows that. How many times in the article did he note it as vgx vs the one time i saw he mistakenly put down vgs.
@joel menkes you also have trouble with basic reading JOEL
Same mistake 2 sentences in a row
Read before you comment JOEL
@Mike Ardelli "you also have trouble with basic reading JOEL"

Nahhh, just i don't have a niggling need to bother with a couple of small spelling errors that you have. Especially when the correct spelling had been used prior and more often.

I figure more important, no, i figure plain and simple important since there's nothing else important to compare against, would be you tell us about what is gonna touch off this tremendous "DNA revolution about to take place", and "a DNA revolution about to take place in 2023". The one many of us, including all the ino shareholders who have been in this one for a long time, a way too long time, that includes me, have seen the promises of for all that time, but not the commercialized products that were supposed to come from it. Whenever it got here.
from what I have read HPV, once contracted is cleared by 90% of people on their own. VGX-3100 treats the other 10% who do not. In both PII and PIII trials 3100 has cleared HPV from 50% of people in the trials. is that not enough to market it as a treatment for HPV?? remember HPV is a main cause of cervical, vulvar and anal cancers....
Personally I think the investment case is around RRP, with that 76% response rate and reducing surgeries. Potentially huge.
@tkarl Correct....PLUS INO 5401 for GBM....VGX 3100 for HPV.....dMAB's are a $Billion dollar opportunity
Smart investors with a long term vision will have the investment of the ages here.....An absolute game changer!
smikhail profile picture
Science is sound but long way to go before any candidate is approved. Previous management team led by Kim was a disaster.
Just One Lab Nerd profile picture
@smikhail - Agreed. Previous management was a mess. I thought about buying into several this years ago (c2014-15), but management action (and inaction) convinced me that this was a bad idea.

I have bought into INO in a small way since it dropped below $2/share last year. With money that I don't 'need' for anything at present and that can sit and wait for a year or two. Also - the fact that Advaccine in China is continuing to work on a COVID application could prove somewhat of a catalyst if they have some success testing on the plasmid vaccine form there. China has got plenty of cases for a vaccine clinical test pool.
sigivanderlust profile picture
company founded in 1979 and there are still a board member from this time..... mgmt poor, boar poor, pipe poor performance no comment..... there are tons of stocks better than this.....
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.